{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+Melanoma+by+AJCC+V7+Stage", "query": { "condition": "Cutaneous Melanoma by AJCC V7 Stage" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 53, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+Melanoma+by+AJCC+V7+Stage&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T12:12:09.451Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02158520", "title": "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Mucosal Melanoma", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-10-18", "completion_date": "2019-10-30", "has_results": true, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 13, "location_summary": "San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02158520" }, { "nct_id": "NCT03325101", "title": "Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Cryosurgery", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Therapeutic Autologous Dendritic Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2017-11-15", "completion_date": "2020-06-14", "has_results": true, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03325101" }, { "nct_id": "NCT07148245", "title": "Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cutaneous Melanoma", "Cutaneous Melanoma, Stage III", "Cutaneous Melanoma by AJCC V7 Stage", "Cutaneous Melanoma, Stage IV" ], "interventions": [ { "name": "Blood Sample", "type": "PROCEDURE" }, { "name": "Health Related Quality of Life Questionnaires (HRQoL)", "type": "OTHER" }, { "name": "Medical Chart Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2025-10-13", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148245" }, { "nct_id": "NCT01587352", "title": "Vorinostat in Treating Patients With Metastatic Melanoma of the Eye", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2012-05-29", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 3, "location_summary": "New York, New York • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01587352" }, { "nct_id": "NCT01364051", "title": "Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Refractory Malignant Solid Neoplasm", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2011-05-25", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01364051" }, { "nct_id": "NCT05334069", "title": "Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Ann Arbor Stage I Lymphoma", "Ann Arbor Stage II Lymphoma", "Ann Arbor Stage III Lymphoma", "Ann Arbor Stage IV Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myeloid Leukemia", "Gastroesophageal Junction Adenocarcinoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Invasive Breast Carcinoma", "Kidney Carcinoma", "Malignant Hepatobiliary Neoplasm", "Malignant Solid Neoplasm", "Melanoma", "Muscle-Invasive Bladder Carcinoma", "RISS Stage I Plasma Cell Myeloma", "RISS Stage II Plasma Cell Myeloma", "RISS Stage III Plasma Cell Myeloma", "Sarcoma", "Stage I Bladder Cancer AJCC v6 and v7", "Stage I Breast Cancer AJCC v7", "Stage I Colorectal Cancer AJCC v6 and v7", "Stage I Esophageal Cancer AJCC V7", "Stage I Gastric Cancer AJCC V7", "Stage I Lung Cancer AJCC v7", "Stage I Ovarian Cancer AJCC v6 and v7", "Stage I Pancreatic Cancer AJCC v6 and v7", "Stage I Prostate Cancer AJCC v7", "Stage I Uterine Corpus Cancer AJCC v7", "Stage II Bladder Cancer AJCC v6 and v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage II Colorectal Cancer AJCC v7", "Stage II Esophageal Cancer AJCC v7", "Stage II Gastric Cancer AJCC v7", "Stage II Lung Cancer AJCC v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage II Pancreatic Cancer AJCC v6 and v7", "Stage II Prostate Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7", "Stage III Bladder Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Esophageal Cancer AJCC v7", "Stage III Gastric Cancer AJCC v7", "Stage III Lung Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage III Prostate Cancer AJCC v7", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IV Bladder Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Esophageal Cancer AJCC v7", "Stage IV Gastric Cancer AJCC v7", "Stage IV Lung Cancer AJCC v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 2000, "start_date": "2022-08-18", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 746, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 501 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05334069" }, { "nct_id": "NCT01217411", "title": "RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Solid Neoplasm", "Extensive Stage Lung Small Cell Carcinoma", "HER2/Neu Negative", "HER2/Neu Positive", "Male Breast Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Recurrent Breast Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Lung Small Cell Carcinoma", "Recurrent Melanoma", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Cognitive Assessment", "type": "PROCEDURE" }, { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Whole-Brain Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2010-10-01", "completion_date": "2011-11-30", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217411" }, { "nct_id": "NCT01807182", "title": "Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Metastatic Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Therapeutic Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-08-20", "completion_date": "2021-08-26", "has_results": true, "last_update_posted_date": "2022-11-10", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807182" }, { "nct_id": "NCT01303341", "title": "Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Recurrent Melanoma", "Refractory Malignant Solid Neoplasm", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Riluzole", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2011-02-18", "completion_date": "2026-09-17", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01303341" }, { "nct_id": "NCT03220009", "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Carcinoma", "Esophageal Carcinoma", "Mucosal Melanoma", "Mucosal Melanoma of the Head and Neck", "Oral Cavity Mucosal Melanoma", "Recurrent Melanoma", "Stage II Vulvar Cancer AJCC v7", "Stage III Vulvar Cancer AJCC v7", "Stage IIIA Vulvar Cancer AJCC v7", "Stage IIIB Vulvar Cancer AJCC v7", "Stage IIIC Vulvar Cancer AJCC v7", "Stage IV Oral Cavity Cancer AJCC v6 and v7", "Stage IV Vulvar Cancer AJCC v7", "Stage IVA Oral Cavity Cancer AJCC v6 and v7", "Stage IVB Oral Cavity Cancer AJCC v6 and v7", "Stage IVC Oral Cavity Cancer AJCC v6 and v7", "Vaginal Carcinoma" ], "interventions": [ { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-11-03", "completion_date": "2021-07-01", "has_results": false, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-06-10T12:12:09.451Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220009" } ] }